Temozolomide nano-in-nanofiber delivery system with sustained release and enhanced cellular uptake by U87MG cells

References

• Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A. 2000;97(12):6242–6244. doi: 10.1073/pnas.97.12.6242.
   PubMed Web of Science ®Google Scholar
• Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001;2(2):120–129. doi: 10.1038/35052535.
   PubMed Web of Science ®Google Scholar
• Sayiner O, Arisoy S, Comoglu T, et al. Development and in vitro evaluation of temozolomide-loaded PLGA nanoparticles in a thermoreversible hydrogel system for local administration in glioblastoma multiforme. J Drug Deliv Sci Technol. 2020;57:101627. doi: 10.1016/j.jddst.2020.101627.
   Web of Science ®Google Scholar
• Senturk F, Cakmak S, Kocum IC, et al. GRGDS-conjugated and curcumin-loaded magnetic polymeric nanoparticles for the hyperthermia treatment of glioblastoma cells. Colloids Surf A Physicochem Eng Asp. 2021;622:126648. doi: 10.1016/j.jddst.2020.101627.
   Web of Science ®Google Scholar
• Delgado‐Martín B, Medina MÁ. Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment. Adv Sci. 2020;7(9):1902971. doi: 10.1002/advs.201902971.
   Web of Science ®Google Scholar
• Batich KA, Reap EA, Archer GE, et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res. 2017;23(8):1898–1909. doi: 10.1158/1078-0432.CCR-16-2057.
   PubMed Web of Science ®Google Scholar
• Leroy HA, Vermandel M, Lejeune JP, et al. Fluorescence guided resection and glioblastoma in 2015: a review. Lasers Surg Med. 2015;47(5):441–451. doi: 10.1002/lsm.22359.
   PubMed Web of Science ®Google Scholar
• Ghandour F, Squassina A, Karaky R, et al. Presenting psychiatric and neurological symptoms and signs of brain tumors before diagnosis: a systematic review. Brain Sci. 2021;11(3):301. doi: 10.3390/brainsci11030301.
   PubMed Web of Science ®Google Scholar
• Hanif F, Muzaffar K, Perveen K, et al. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9. doi: 10.22034/APJCP.2017.18.1.3.
   PubMedGoogle Scholar
• Ellor SV, Pagano-Young TA, Avgeropoulos NG. Glioblastoma: background, standard treatment paradigms, and supportive care considerations. J Law Med Ethics. 2014;42(2):171–182. doi: 10.1111/jlme.12.
   PubMed Web of Science ®Google Scholar
• Shetty K, Yasaswi S, Dutt S, et al. Multifunctional nanocarriers for delivering siRNA and miRNA in glioblastoma therapy: advances in nanobiotechnology-based cancer therapy. 3 Biotech. 2022;12(11):301. doi: 10.1007/s13205-022-03365-2.
   PubMedGoogle Scholar
• Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE. RNA interference for glioblastoma therapy: innovation ladder from the bench to clinical trials. Life Sci. 2017;188:26–36. doi: 10.1016/j.lfs.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887–2893. doi: 10.1245/s10434-008-0048-2.
   PubMed Web of Science ®Google Scholar
• Korgaonkar N, Yadav KS. Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy. Life Sci. 2019;239:117060. doi: 10.1016/j.lfs.2019.117060.
   PubMed Web of Science ®Google Scholar
• Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21(8):1624–1636. doi: 10.1200/JCO.2003.05.063.
   PubMed Web of Science ®Google Scholar
• Berman JI, Berger MS, Mukherjee P, et al. Diffusion-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with gliomas. J Neurosurg. 2004;101(1):66–72. doi: 10.3171/jns.2004.101.1.0066.
   PubMed Web of Science ®Google Scholar
• Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumor barrier in brain tumors and metastases. Nat Rev Cancer. 2020;20(1):26–41. doi: 10.1038/s41568-019-0205-x.
   PubMed Web of Science ®Google Scholar
• Bianco J, Bastiancich C, Jankovski A, et al. On glioblastoma and the search for a cure: where do we stand? Cell Mol Life Sci. 2017;74(13):2451–2466. doi: 10.1007/s00018-017-2483-3.
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood–brain and blood–tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2(1):45–59. doi: 10.1093/neuonc/2.1.45.
   PubMed Web of Science ®Google Scholar
• Mo F, Pellerino A, Soffietti R, et al. Blood–brain barrier in brain tumors: biology and clinical relevance. Int J Mol Sci. 2021;22(23):12654. doi: 10.3390/ijms222312654.
   PubMed Web of Science ®Google Scholar
• Lehmann F, Wennerberg J. Evolution of nitrogen-based alkylating anticancer agents. Processes. 2021;9(2):377. doi: 10.3390/pr9020377.
   Web of Science ®Google Scholar
• Strobel H, Baisch T, Fitzel R, et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines. 2019;7(3):69. doi: 10.3390/biomedicines7030069.
   PubMed Web of Science ®Google Scholar
• Yasaswi PS, Shetty K, Yadav KS. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. J Control Release. 2021;336:549–571. doi: 10.1016/j.jconrel.2021.07.003.
   PubMed Web of Science ®Google Scholar
• Zhang J, Stevens MFG, Bradshaw DT. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5(1):102–114. doi: 10.2174/1874-470211205010102.
   PubMedGoogle Scholar
• Silber JR, Bobola MS, Blank A, et al. O6-Methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta. 2012;1826(1):71–82. doi: 10.1016/j.bbcan.2011.12.004.
   PubMed Web of Science ®Google Scholar
• Fang C, Wang K, Stephen ZR, et al. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces. 2015;7(12):6674–6682. doi: 10.1021/am5092165.
   PubMed Web of Science ®Google Scholar
• Senturk F, Cakmak S, Gumusderelioglu M, et al. Hydrolytic instability and low-loading levels of temozolomide to magnetic PLGA nanoparticles remain challenging against glioblastoma therapy. J Drug Deliv Sci Technol. 2022;68:103101. doi: 10.1016/j.jddst.2022.103101.
   Web of Science ®Google Scholar
• Fulfager AD, Yadav KS. Understanding the implications of co-delivering therapeutic agents in a nanocarrier to combat multidrug resistance (MDR) in breast cancer. J Drug Deliv Sci Technol. 2021;62:102405. doi: 10.1016/j.jddst.2021.102405.
   Web of Science ®Google Scholar
• Li J, Zhao J, Tan T, et al. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J Nanomedicine. 2020;15:2563–2582. doi: 10.2147/IJN.S243223.
   PubMed Web of Science ®Google Scholar
• Shetty K, Bhandari A, Yadav KS. Nanoparticles incorporated in nanofibers using electrospinning: a novel nano-in-nano delivery system. J Control Release. 2022;350:421–434. doi: 10.1016/j.jconrel.2022.08.035.
   PubMed Web of Science ®Google Scholar
• Jain R, Shetty S, Yadav KS. Unfolding the electrospinning potential of biopolymers for preparation of nanofibers. J Drug Deliv Sci Technol. 2020;57:101604. doi: 10.1016/j.jddst.2020.101604.
   Web of Science ®Google Scholar
• Yadav KS, Mishra DK, Deshpande A, et al. Levels of drug targeting. In: Tekade RK (eds), Basic fundamentals of drug delivery. London: Academic Press; 2019. p. 269–305. doi: 10.1016/B978-0-12-817909-3.00007-8.
   Google Scholar
• Tseng YY, Yang TC, Wang YC, et al. Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. Int J Nanomedicine. 2017;12:1265–1276. doi: 10.2147/IJN.S124593.
   PubMed Web of Science ®Google Scholar
• Chen S, Boda SK, Batra SK, et al. Emerging roles of electrospun nanofibers in cancer research. Adv Healthc Mater. 2018;7(6):1701024. doi: 10.1002/adhm.201701024.
   Web of Science ®Google Scholar
• Anup N, Chavan T, Chavan S, et al. Reinforced electrospun nanofiber composites for drug delivery applications. J Biomed Mater Res A. 2021;109(10):2036–2064. doi: 10.1002/jbm.a.37187.
   PubMed Web of Science ®Google Scholar
• Jannesari M, Varshosaz J, Morshed M, et al. Composite poly(vinyl alcohol)/poly(vinyl acetate) electrospun nanofibrous mats as a novel wound dressing matrix for controlled release of drugs. Int J Nanomedicine. 2011;6:993–1003. doi: 10.2147/IJN.S17595.
   PubMed Web of Science ®Google Scholar
• Khramtsov P, Burdina O, Lazarev S, et al. Modified desolvation method enables simple one-step synthesis of gelatin nanoparticles from different gelatin types with any bloom values. Pharmaceutics. 2021;13(10):1537. doi: 10.3390/pharmaceutics13101537.
   PubMed Web of Science ®Google Scholar
• Ahsan SM, Rao CM. The role of surface charge in the desolvation process of gelatin: implications in nanoparticle synthesis and modulation of drug release. Int J Nanomedicine. 2017;12:795–808. doi: 10.2147/IJN.S124938.
   PubMed Web of Science ®Google Scholar
• Nahar M, Mishra D, Dubey V, et al. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine. 2008;4(3):252–261. doi: 10.1016/j.nano.2008.03.007.
   PubMed Web of Science ®Google Scholar
• Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release. 2013;172(3):1075–1091. doi: 10.1016/j.jconrel.2013.09.019.
   PubMed Web of Science ®Google Scholar
• Yang D, Li Y, Nie J. Preparation of gelatin/PVA nanofibers and their potential application in controlled release of drugs. Carbohydr Polym. 2007;69(3):538–543. doi: 10.1016/j.carbpol.2007.01.008.
   Web of Science ®Google Scholar
• Soni G, Yadav KS, Gupta MK. Design of experiments (DoE) approach to optimize the sustained release microparticles of gefitinib. Curr Drug Deliv. 2019;16(4):364–374. doi: 10.2174/1567201816666181227114109.
   PubMed Web of Science ®Google Scholar
• Jain D, Bajaj A, Athawale R, et al. Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies. Drug Deliv. 2016;23(3):999–1016. doi: 10.3109/10717544.2014.926574.
   PubMed Web of Science ®Google Scholar
• Shamsipour M, Mansouri AM, Moradipour P. Temozolomide conjugated carbon quantum dots embedded in core/shell nanofibers prepared by coaxial electrospinning as an implantable delivery system for cell imaging and sustained drug release. AAPS PharmSciTech. 2019;20(7):259. doi: 10.1208/s12249-019-1466-0.
   PubMed Web of Science ®Google Scholar
• Guo Z, Sui J, Ma M, et al. pH-responsive charge switchable PEGylated ε-poly-l-lysine polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment. J Control Release. 2020;326:350–364. doi: 10.1016/j.jconrel.2020.07.030.
   PubMed Web of Science ®Google Scholar
• Weidemann H, Feger D, Ehlert JE, et al. Markedly divergent effects of ouabain on a temozolomide-resistant (T98G) vs. a temozolomide-sensitive (LN229) glioblastoma cell line. Discov Oncol. 2023;14(1):27. doi: 10.1007/s12672-023-00633-2.
   PubMedGoogle Scholar
• Silva VL, Kaassis A, Dehsorkhi A, et al. Enhanced selectivity, cellular uptake, and in vitro activity of an intrinsically fluorescent copper–tirapazamine nanocomplex for hypoxia targeted therapy in prostate cancer. Biomater Sci. 2020;8(9):2420–2433. doi: 10.1039/C9BM01905G.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan S, Xiao D, et al. Novel silyl ether-based acid-cleavable antibody–MMAE conjugates with appropriate stability and efficacy. Cancers. 2019;11(7):957. doi: 10.3390/cancers11070957.
   PubMed Web of Science ®Google Scholar
• Yu C, Morshed R, Auffinger B, et al. Multifunctional nanoparticles for brain tumor diagnosis and therapy. Adv Drug Deliv Rev. 2014;66(1):42–57. doi: 10.1016/j.addr.2013.09.006.
   PubMed Web of Science ®Google Scholar
• Li Y, He H, Jia X, et al. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33(15):3899–3908. doi: 10.1016/j.biomaterials.2012.02.004.
   PubMed Web of Science ®Google Scholar
• Karavasili C, Panteris E, Vizirianakis IS, et al. Chemotherapeutic delivery from a self-assembling peptide nanofiber hydrogel for the management of glioblastoma. Pharm Res. 2018;35(8):1–13. doi: 10.1007/s11095-018-2442-1.
   Web of Science ®Google Scholar
• Varanko A, Saha S, Chilkoti A. Recent trends in protein and peptide-based biomaterials for advanced drug delivery. Adv Drug Deliv Rev. 2020;156:133–187. doi: 10.1016/j.addr.2020.08.008.
   PubMed Web of Science ®Google Scholar
• Saxena A, Sachin K, Bohidar HB, et al. Effect of molecular weight heterogeneity on drug entrapment efficiency of gelatin nano-particles. Colloids Surf B Biointerfaces. 2005;45(1):42–48. doi: 10.1016/j.colsurfb.2005.07.005.
   PubMed Web of Science ®Google Scholar
• Shamarekh KS, Gad HA, Soliman ME, et al. Towards the production of monodisperse gelatin nanoparticles by modified one step desolvation technique. J Pharm Investig. 2020;50(2):189–200. doi: 10.1016/j.colsurfb.2005.07.005.
   Web of Science ®Google Scholar
• Zhang W, He Z, Han Y, et al. Structural design and environmental applications of electrospun nanofibers. Compos A Appl Sci Manuf. 2020;137:106009. doi: 10.1016/j.colsurfb.2005.07.005.
   PubMed Web of Science ®Google Scholar
• Soni G, Kale K, Shetty S, et al. Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer. Heliyon. 2020;6(4):e03846. doi: 10.1016/j.heliyon.2020.e03846.
   PubMed Web of Science ®Google Scholar
• Yeo Y, Park K. Control of entrapment efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res. 2004;27(1):1–12. doi: 10.1007/BF02980037.
   PubMed Web of Science ®Google Scholar
• Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59(1):177–187. doi: 10.1016/j.ejpb.2004.06.009.
   PubMed Web of Science ®Google Scholar
• Tan H, Sun G, Lin W, et al. Gelatin particle-stabilized high internal phase emulsions as nutraceutical containers. ACS Appl Mater Interfaces. 2014;6(16):13977–13984. doi: 10.1021/am503341j.
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Li X, Lu CT, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 2014;10(4):755–764. doi: 10.1016/j.nano.2013.10.009.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK. Formulation and optimization of temozolomide nanoparticles by 3 factor 2 level factorial design. Biomatter. 2013;3(2):e25102. doi: 10.4161/biom.25102.
   PubMedGoogle Scholar
• Prakash J, Venkataprasanna KS, Bharath G, et al. In-vitro evaluation of electrospun cellulose acetate nanofiber containing graphene oxide/TiO2/curcumin for wound healing application. Colloids Surf A Physicochem Eng Asp. 2021;627:127166. doi: 10.1016/j.colsurfa.2021.127166.
   Web of Science ®Google Scholar
• Yan E, Jiang J, Yang X, et al. pH-sensitive core-shell electrospun nanofibers based on polyvinyl alcohol/polycaprolactone as a potential drug delivery system for the chemotherapy against cervical cancer. J Drug Deliv Sci Technol. 2020;55:101455. doi: 10.1016/j.jddst.2019.101455.
   Web of Science ®Google Scholar
• He S, Jiang L, Liu J, et al. Electrospun PVA/gelatin based nanofiber membranes with synergistic antibacterial performance. Colloids Surf A Physicochem Eng Asp. 2022;637:128196. doi: 10.1016/j.colsurfa.2021.128196.
   Web of Science ®Google Scholar
• Gaihre B, Khil MS, Lee DR, et al. Gelatin-coated magnetic iron oxide nanoparticles as carrier system: drug loading and in vitro drug release study. Int J Pharm. 2009;365(1–2):180–189. doi: 10.1016/j.ijpharm.2008.08.020.
   PubMed Web of Science ®Google Scholar
• Jain DS, Athawale RB, Bajaj AN, et al. Unraveling the cytotoxic potential of temozolomide loaded into PLGA nanoparticles. Daru. 2014;22(1):18. doi: 10.1186/2008-2231-22-18.
   PubMedGoogle Scholar
• Ling Y, Wei K, Zou F, et al. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int J Pharm. 2012;430(1–2):266–275. doi: 10.1016/j.ijpharm.2012.03.047.
   PubMedGoogle Scholar
• Tavakoli R, Vakilian S, Jamshidi-Adegani F, et al. Prolonged drug release using PCL–TMZ nanofibers induce the apoptotic behavior of U87 glioma cells. Int J Polym Mater Polym Biomater. 2018;67(15):873–878. doi: 10.1080/00914037.2017.1393677.
   Web of Science ®Google Scholar
• Soni G, Yadav KS. Applications of nanoparticles in treatment and diagnosis of leukemia. Mater Sci Eng C Mater Biol Appl. 2015;47:156–164. doi: 10.1016/j.msec.2014.10.043.
   PubMed Web of Science ®Google Scholar
• Augustine R, Hasan A, Primavera R, et al. Cellular uptake and retention of nanoparticles: insights on particle properties and interaction with cellular components. Mater Today Commun. 2020;25:101692. doi: 10.1016/j.mtcomm.2020.101692.
   Web of Science ®Google Scholar